MBP146-78
CAS No. 188343-77-3
MBP146-78( —— )
Catalog No. M20725 CAS No. 188343-77-3
MBP146-78 is a potent and selective cGMP inhibitor dependent protein kinases.
MBP146-78 is a potent and selective cGMP inhibitor dependent protein kinases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
2MG | 71 | In Stock |
|
5MG | 87 | In Stock |
|
10MG | 132 | In Stock |
|
25MG | 294 | In Stock |
|
50MG | 492 | In Stock |
|
100MG | 701 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMBP146-78
-
NoteResearch use only, not for human use.
-
Brief DescriptionMBP146-78 is a potent and selective cGMP inhibitor dependent protein kinases.
-
DescriptionMBP146-78 is a potent and selective cGMP inhibitor dependent protein kinases.
-
In VitroMBP146-78 displays a dose-dependent inhibition of T. gondii tachyzoites replicating inside HFFs, with an IC50 of 210 nM. The suppression of lytic parasite growth by MBP146-78 is reversible. Replacement of the medium with medium lacking MBP146-78, after treatment for up to 7 days at 2 μM, results in complete lysis of HFF cell monolayers. MBP146-78 is neither toxic nor inhibitory to proliferating or confluent monolayers of HFFs at concentrations of up to 10 μM.
-
In VivoIn infected mice that are treated with MBP146-78 at 50 mg/kg twice daily, parasites are undetectable throughout the 10-day treatment period in each of the tissues examined. However, samples from brain, spleen, and lung taken from infected treated mice reveal the presence of parasites after cessation of administration of MBP146-78, indicating that a transient asymptomatic parasite recrudescence occurs in all survivors. The ability of mice to control Toxoplasma infection after MBP146-78 treatment has been terminated suggests that the mouse immune system plays a synergistic role with chemotherapy in controlling the infection.
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetParasite
-
RecptorcGMP
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number188343-77-3
-
Formula Weight335.42
-
Molecular FormulaC21H22FN3
-
Purity>98% (HPLC)
-
SolubilityDMSO:7.69 mg/mL (22.93 mM)
-
SMILESCN1CCC(CC1)c1cc(c([nH]1)-c1ccc(F)cc1)-c1ccncc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Nare B Allocco J J Liberator P A et al. Evaluation of a Cyclic GMP-Dependent Protein Kinase Inhibitor in Treatment of Murine Toxoplasmosis: Gamma Interferon Is Required for Efficacy[J]. Antimicrobial Agents and Chemotherapy 2002 46(2):300-307.
molnova catalog
related products
-
Febrifugine dihydroc...
Febrifugine dihydrochloride is a biochemical with therapeutic activity regarding malaria, cancer, fibrosis and inflammatory diseases.
-
ELQ-300
ELQ-300 is bioavailable antimalarial agent acts as an inhibitor of the reductive (Qi) site of the cytochrome bc1 complex (cyt bc1).
-
GNF179
GNF179 is an optimized 8,8-dimethyl IP analog.